NASDAQ:ACHN - Achillion Pharmaceuticals, Inc.
$2.50
 $0.03
+1.21%
4:20PM EDT
2019-02-22
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ACHN     avg for
industry  
  avg for
sector  
42 stocks weight:  36. 05   0. 00   0. 00  
42 stocks rank:  3. 10 K 2. 00 K 1. 08 K
# analyst opinions:  4. 00   14. 68   14. 18  
mean recommendation:  1. 80   1. 96   1. 94  

quick ratio:  32. 72   5. 17   1. 75  
current ratio:  33. 21   5. 48   2. 10  

target price low:  5. 00   90. 05   118. 16  
target price avg:  5. 50   115. 98   142. 03  
target price high:  6. 00   141. 44   162. 86  
1-yr high:  4. 23   124. 28   143. 16  
last close:  2. 50   102. 75   129. 63  
50-day avg:  2. 14   98. 90   122. 76  
200-day avg:  2. 84   100. 04   123. 17  
1-yr low:  1. 31   78. 22   100. 14  
volume:  856. 85 K 2. 36 M 4. 94 M
50-day avg volume:  2. 38 M 3. 14 M 4. 85 M
200-day avg volume:  1. 58 M 3. 12 M 4. 26 M

1-day return:  1. 21 % 1. 74 % 0. 96 %
this week return:  5. 04 % -0. 72 % -0. 25 %
12-wk return:  -13. 49 % 1. 23 % -0. 75 %
52-wk return:  -16. 95 % -2. 03 % 16. 23 %

enterprise value (EV):  48. 01 M 54. 82 B 107. 48 B
market cap:  346. 52 M 47. 12 B 97. 54 B
EBITDA:  -79. 05 M 4. 72 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 61   9. 03   16. 84  
total debt:  169. 00 K 13. 41 B 16. 70 B
debt/equity:  0. 06   41. 61   80. 63  
net income (common):  -76. 87 M 2. 34 B 3. 61 B

shares outstanding:  138. 62 M 594. 48 M 1. 22 B
shares:  124. 60 M 592. 96 M 1. 15 B
shares short:  10. 60 M 10. 54 M 11. 92 M
shares short prior month:  7. 43 M 11. 90 M 11. 87 M
short ratio:  5. 42   4. 86   3. 18  
total cash/share:  2. 04   11. 99   10. 04  
total cash:  282. 07 M 7. 30 B 7. 05 B
free cash flow:  -44. 70 M 176. 15 M 2. 43 B
operating cash flow:  -70. 56 M 277. 94 M 3. 06 B

book value:  2. 02   15. 06   28. 80  
price/book:  1. 24   -0. 58   -2. 51  
gross profits:  -65. 05 M 8. 33 B 19. 31 B
operating margins:  0. 00 % -466. 96 % -635. 17 %
EBITDA margins:  0. 00 % 13. 54 % 22. 51 %
profit margins:  0. 00 % 6. 67 % 10. 02 %
gross margins:  0. 00 % 48. 21 % 54. 28 %

1-yr max volatility:  -22. 83 % --- ---
1-yr mean volatility:  0. 07 % 0. 01 % 0. 07 %

1-yr EPS:  -0. 56   3. 08   4. 11  
forward EPS:  -0. 68   4. 75   7. 18  
P/E:  -4. 50   15. 54   29. 27  
forward P/E:  -3. 63   -20. 90   3. 33  
PE/G:  0. 27   1. 33   6. 07  
growth:  -16. 66 % 755. 42 % 114. 65 %
earnings high:  -0. 14   1. 33   1. 68  
earnings avg:  -0. 15   0. 97   1. 54  
earnings low:  -0. 16   0. 70   1. 41  
revenue high:  -0. 00   2. 81 B 11. 37 B
revenue avg:  -0. 00   2. 70 B 11. 06 B
revenue low:  -0. 00   2. 61 B 10. 84 B
return on assets:  -15. 43 % -3. 63 % 3. 73 %
return on equity:  -24. 55 % 102. 34 % 26. 90 %

beta (1yr vs S&P500):  1. 38   1. 22   0. 94  
sharpe (1yr):  0. 24   0. 14   1. 05  

held % insiders:  0. 15 % 6. 40 % 3. 16 %
held % institutions:  79. 35 % 79. 62 % 70. 81 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-22 : ACHN
.    + 1.025 =         1.025 :: INITIAL WEIGHT
.  + 358.642 =       359.667 :: inverse volume-to-price addition
.  + 395.563 =        755.23 :: spline projection addition
.  - 163.706 =       591.524 :: poor performance penalty
.    x 0.897 =       530.594 :: one-year gains+dividend factor
.    x 7.757 =      4115.761 :: 13 weeks' performance factor
.    x 1.478 =      6082.865 :: industry recommendation factor
.    x 2.342 =     14243.592 :: symbol recommendation factor
.    x 0.998 =     14221.613 :: return on assets factor
.    x 0.998 =     14186.697 :: return on equity factor
.    x 5.169 =     73327.534 :: current ratio factor
.    x 1.016 =     74474.529 :: quick ratio factor
.    x 1.088 =     81054.221 :: short ratio factor
.    x 2.012 =    163109.605 :: price-to-book factor
.    x 1.001 =     163227.15 :: debt-to-equity factor
.    x 1.142 =    186479.967 :: 5-day avg > 50-day avg
.    x 2.099 =    391508.334 :: P/E weight
.    x 1.387 =    543191.282 :: PE/G factor
.    x 1.593 =    865422.152 :: beta factor
.    x 0.241 =    208301.942 :: sharpe factor
.    x 2.119 =    441491.261 :: target low factor
.    x 1.365 =    602701.077 :: target mean factor
.    x 1.118 =     674013.63 :: target high factor
.    x 1.012 =    682312.062 :: industry 12-weeks return
.      x 1.0 =    682082.078 :: overall "drift" factor
.    x 0.999 =    681402.093 :: largest single-day jump factor
.    x 0.068 =     46417.036 :: low price factor
.      x 1.0 =     46412.226 :: factor hist industry gain for week 07
.     x 1.01 =     46864.959 :: upcoming earnings report factor
.   cubeRoot =        36.054 :: reduced for readability
.                     36.054 :: FINAL WEIGHT for NASDAQ:ACHN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org